C12N 2720/12143
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2720/12143 (Viral genome or elements thereof as genetic vector) appears on 4 US grants and 7 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 7
- Assignees
- 3
- Inventors
- 16
- Latest grant
- 2 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 2 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 0 |
| 2021 | 1 | 1 |
| 2022 | 0 | 0 |
| 2023 | 1 | 0 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Cancer therapy compositions and uses thereof2 Dec 2025US 12,485,163 B2HDT Bio Corp.
- Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine7 Feb 2023US 11,571,471 B2Bavarian Nordic A/S
- Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine5 Jan 2021US 10,881,725 B2Bavarian Nordic A/S
- Method of rapidly producing improved vaccines for animals26 Jun 2018US 10,004,797 B2Harrisvaccines, Inc.
- Cancer therapy compositions and uses thereof19 Feb 2026US 2026/0048108 A1HDT Bio Corp.
- Cancer therapy compositions and uses thereof4 Jul 2024US 2024/0216493 A1HDT Bio Corp.
- Recombinant Modified Vaccinia Virus Ankara (MVA) Equine Encephalitis Virus Vaccine8 Jul 2021US 2021/0205439 A1Bavarian Nordic A/S
- Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine7 Feb 2019US 2019/0038739 A1Bavarian Nordic A/S
- Method of rapidly producing improved vaccines for animals11 Jun 2015US 2015/0157703 A1Harrisvaccines, Inc.
Most cited
By later US patents